Clinical Trials for Kidney Cancer

A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolls children/AYA age >12 months to <30 years with recurrent/refractory non-CNS solid tumors (dose-finding/expansion, including an HRR-altered cohort) and randomizes patients with first-relapse, EWSR1-rearranged Ewing sarcoma to compare efficacy. Treatment is nanoliposomal irinotecan (Onivyde; topoisomerase I–mediated DNA damage) on days 1 and 8 of 21-day cycles combined with either talazoparib (PARP1/2 inhibitor with PARP-trapping) or temozolomide (oral DNA-alkylating agent).

ClinicalTrials.gov ID: NCT04901702

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with ECOG 0–1 and advanced CD70-expressing malignancies needing additional therapy: ccRCC after ≥1 prior line including ICI+TKI, DLBCL/high-grade B-cell lymphoma after ≥2 prior lines including immunochemotherapy and salvage, peripheral T-cell lymphoma after ≥1 systemic therapy, or CTCL (mycosis fungoides/Sézary) stage IIB+ with B0/B1 blood involvement after ≥1 systemic therapy. Participants receive INCA036873 monotherapy, an investigational CD70×CD3 bispecific T-cell engager intended to redirect T cells to kill CD70-positive tumor cells.

ClinicalTrials.gov ID: NCT07195916

Selective Antigen Specific dTβRII-expressing T Cells and B7-H3 CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are children, adolescents, and young adults (age 1 to <24 years; >10 kg) with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor with measurable/evaluable disease after standard therapies and no known CNS involvement. After fludarabine/cyclophosphamide lymphodepletion, participants receive a single infusion of an autologous 1:1 cellular product combining B7-H3–targeted CAR T cells with PRAME antigen–specific T cells engineered with a dominant-negative TGF-β receptor II (dTβRII) to resist TGF-β–mediated immunosuppression.

ClinicalTrials.gov ID: NCT07172958

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced selected solid tumors, including SCLC, extrapulmonary high-grade neuroendocrine/small-cell carcinomas, NSCLC, prostate, ovarian, renal, HNSCC, hepatic, gastric, and triple-negative breast cancers, after progression/relapse/intolerance to at least one standard systemic therapy. All patients receive dose-escalated oral EXS74539/REC-4539 monotherapy, a selective reversible LSD1/KDM1A epigenetic inhibitor, to define safety and MTD with preliminary efficacy assessment.

ClinicalTrials.gov ID: NCT07517198

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726 in Patients With Advanced Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and refractory/relapsed locally advanced unresectable or metastatic solid tumors, including post–PD-1/PD-L1 treated RCC, HCC, gastroesophageal cancer, and endometrial cancer, receive CTX-10726 monotherapy IV every 2 weeks. CTX-10726 is an investigational tetravalent bispecific antibody targeting PD-1 and VEGF-A to combine checkpoint blockade with anti-angiogenic activity.

ClinicalTrials.gov ID: NCT07419841

A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Children and young adults aged 2–39 years with measurable, unresectable recurrent or refractory Wilms tumor or desmoplastic small round cell tumor receive IV trastuzumab deruxtecan every 21 days. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor payload to HER2-expressing tumor cells.

ClinicalTrials.gov ID: NCT04616560

A Phase 1 Study Of LNK001 (Dual ENPP3/CAIX AND-gate CAR T Cell Therapy) In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic clear-cell–component renal cell carcinoma, ECOG 0–1, measurable disease, and ≥50% tumor CAIX expression after prior PD-1/PD-L1 inhibitor and tyrosine kinase inhibitor therapy receive fludarabine/cyclophosphamide lymphodepletion followed by autologous LNK001 CAR-T cells. LNK001 uses a dual-receptor CAIX/ENPP3 Boolean AND-gate designed to activate preferentially against tumor cells coexpressing both targets.

ClinicalTrials.gov ID: NCT07564232

An Open-Label, Multicenter, Phase 1a/1b, Dose Escalation/Dose Expansion Clinical Trial of Theranostic Pair PD-32766D, a 64Cu-Labeled Peptide and PD-32766T, an 225Ac-Labeled Peptide Targeting Carbonic Anhydrase IX in Adult Participants With Relapsed or Refractory Clear Cell Renal Cell Carcinoma Who Have Progressed From or Could Not be Administered Due to Medical Unsuitability or Limited Access to All Standard of Care Therapies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic clear cell renal cell carcinoma who have exhausted, cannot medically receive, or lack access to standard therapies and have CAIX-positive uptake on PD-32766D PET imaging receive intravenous PD-32766T, an actinium-225–labeled CAIX-targeting peptide that delivers localized alpha radiation. Treatment is dose-escalated and expanded for up to six cycles.

ClinicalTrials.gov ID: NCT07688187

A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.

ClinicalTrials.gov ID: NCT04787042

Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls patients aged 18 and older with advanced solid tumors, including RCC, CRPC, NSCLC, SCCHN, CRC, endometrial, and ovarian cancers, who have failed or are ineligible for standard treatments, to evaluate TT-10, an adenosine A2A receptor antagonist, and TT-4, an adenosine A2B receptor antagonist, administered as single agents and in combination.

ClinicalTrials.gov ID: NCT04969315